文献速递胸部肿瘤

基于42 Gy时[18F]FDG-PET肿瘤残留摄取的自适应放疗(至74 Gy)或标准放疗(66 Gy)治疗III期非小细胞肺癌:多中心、随机、对照2期试验(RTEP7-IFCT-1402)

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-08-09

这项多中心、随机、对照、非比较性2期试验纳入158例不可手术的III期非小细胞肺癌患者,按42 Gy时[18F]FDG-PET残留代谢情况给予自适应放疗(阳性者 boost 至74 Gy)或标准66 Gy放疗。15个月局部控制率A组77.6%(95%CI 67.6-87.6%)vs B组71.2%(95%CI 60.8-81.6%),两组急性3-4级不良事件在危及器官方面无差异。

要点

  • A组15个月局部控制率77.6% vs B组71.2%,95%CI分别为67.6-87.6%和60.8-81.6%。
  • A组急性3-4级不良事件20/68(29%)vs B组33/73(45%),严重不良事件5/68(7%)vs 10/73(14%)。
  • 作者认为该[18F]FDG-PET引导的剂量适应值得开展随机3期评估。

核心结论

  • 基于 interim [18F]FDG-PET 的胸部放疗 boost 获得了有意义的局部控制率,两组在危及器官方面不良事件无差异,与此前胸部放疗 intensify 的尝试形成对比,作者认为值得对 such [18F]FDG-PET 引导的放疗剂量适应在III期NSCLC患者中开展随机3期评估。

研究设计与样本

  • 多中心、随机、对照、非比较性2期试验,2015年11月12日至2021年7月7日随机分配158例患者(女性47例[30%],男性111例[70%])至boost放疗A组(81例[51%])或标准放疗B组(77例[49%])。
  • 入组标准为18岁及以上、不可手术的III期NSCLC、无EGFR突变或ALK重排、ECOG体能状态0-1、可评估肿瘤或淋巴结病灶、肺功能保留且适合根治性放化疗。
  • 随机采用中央交互式网络应答系统,非盲法,1:1,最小化法(随机因子0.8),按放疗技术(调强放疗 vs 三维适形放疗)和治疗中心分层。
  • 主要终点为接受至少一剂同步放化疗的合格患者的15个月局部控制率。

主要发现

  • A组80例(99%)接受诱导化疗,68例(84%)接受放化疗,其中48例(71%)在42 Gy后[18F]FDG-PET有残留摄取并接受放疗boost;B组全部77例接受诱导化疗,73例(95%)接受放化疗。
  • 接受放化疗的合格患者(n=140)中位随访45.1个月(95%CI 39.3-48.3)。
  • 15个月局部控制率A组77.6%(95%CI 67.6-87.6%)vs B组71.2%(95%CI 60.8-81.6%)。
  • 急性(放化疗开始后90天内)3-4级不良事件A组20/68(29%)vs B组33/73(45%),严重不良事件A组5/68(7%)vs B组10/73(14%)。
  • 最常见3-4级不良事件为发热性中性粒细胞减少(A组7/68[10%] vs B组16/73[22%])和贫血(A组5/68[7%] vs B组9/73[12%]);急性期B组死亡2例(3%),A组无死亡。

关键数值与推荐

  • A组:42 Gy时[18F]FDG-PET阳性残留代谢者接受boost放疗至74 Gy/33次,其余患者接受标准66 Gy/33次/6.5周。
  • B组:标准放疗66 Gy/33次/6.5周。
  • 所有患者接受两周期诱导铂类化疗(紫杉醇175 mg/m2静脉每3周一次+卡铂AUC=6每3周一次,或顺铂80 mg/m2静脉每3周一次+长春瑞滨第1天30 mg/m2静脉、第8天60 mg/m2口服[或30 mg/m2静脉]每3周一次),随后同步放化疗(8周内三周期,每周紫杉醇40 mg/m2静脉+卡铂AUC=2,或顺铂80 mg/m2静脉+长春瑞滨第1天20 mg/m2静脉、第8天40 mg/m2口服[或20 mg/m2静脉],21天为一周期)。

临床怎么用

  • 作者认为基于interim [18F]FDG-PET的胸部放疗boost值得开展随机3期评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic radiation intensification is debated in patients with stage III non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of a boost radiotherapy dose up to 74 Gy in a functional sub-volume given according to on-treatment [18F]fluorodeoxyglucose ([18F]FDG)-PET results. METHODS: In this multicentre, randomised, controlled non-comparative phase 2 trial, we recruited patients aged 18 years or older with inoperable stage III NSCLC without EGFR mutation or ALK rearrangement with an Eastern Cooperative Oncology Group performance status of 0-1, and who were affiliated with or a beneficiary of a social benefit system, with evaluable tumour or node lesions, preserved lung function, and who were amenable to curative-intent radiochemotherapy. Patients were randomly allocated using a central interactive web-response system in a non-masked method (1:1; minimisation method used [random factor of 0·8]; stratified by radiotherapy technique [intensity-modulated radiotherapy vs three-dimensional conformal radiotherapy] and by centre at which patients were treated) either to the experimental adaptive radiotherapy group A, in which only patients with positive residual metabolism on [18F]FDG-PET at 42 Gy received a boost radiotherapy (up to 74 Gy in 33 fractions), with all other patients receiving standard radiotherapy dosing (66 Gy in 33 fractions over 6·5 weeks), or to the standard radiotherapy group B (66 Gy in 33 fractions) over 6·5 weeks. All patients received two cycles of induction platinum-based chemotherapy cycles (paclitaxel 175 mg/m2 intravenously once every 3 weeks and carboplatin area under the curve [AUC]=6 once every 3 weeks, or cisplatin 80 mg/m2 intravenously once every 3 weeks and vinorelbine 30 mg/m2 intravenously on day 1 and 60 mg/m2 orally [or 30 mg/m2 intravenously] on day 8 once every 3 weeks). Then they concomitantly received radiochemotherapy with platinum-based chemotherapy (three cycles for 8 weeks, with once per week paclitaxel 40 mg/m2 intravenously and carboplatin AUC=2 or cisplatin 80 mg/m2 intravenously and vinorelbine 20 mg/m2 intravenously on day 1 and 40 mg/m2 orally (or 20 mg/m2 intravenously) on day 8 in 21-day cycles). The primary endpoint was the 15-month local control rate in the eligible patients who received at least one dose of concomitant radiochemotherapy. This RTEP7-IFCT-1402 trial is registered with ClinicalTrials.gov (NCT02473133), and is ongoing. FINDINGS: From Nov 12, 2015, to July 7, 2021, we randomly assigned 158 patients (47 [30%] women and 111 [70%] men) to either the boosted radiotherapy group A (81 [51%]) or to the standard radiotherapy group B (77 [49%)]. In group A, 80 (99%) patients received induction chemotherapy and 68 (84%) received radiochemotherapy, of whom 48 (71%) with residual uptake on [18F]FDG-PET after 42 Gy received a radiotherapy boost. In group B, all 77 patients received induction chemotherapy and 73 (95%) received radiochemotherapy. At the final analysis, the median follow-up for eligible patients who received radiochemotherapy (n=140) was 45·1 months (95% CI 39·3-48·3). The 15-month local control rate was 77·6% (95% CI 67·6-87·6%) in group A and 71·2% (95% CI 60·8-81·6%) in group B. Acute (within 90 days from radiochemotherapy initiation) grade 3-4 adverse events were observed in 20 (29%) of 68 patients in group A and 33 (45%) of 73 patients in group B, including serious adverse events in five (7%) patients in group A and ten (14%) patients in group B. The most common grade 3-4 adverse events were febrile neutropenia (seven [10%] of 68 in group A vs 16 [22%] of 73 in group B), and anaemia (five [7%] vs nine [12%]). In the acute phase, two deaths (3%) occurred in group B (one due to a septic shock related to chemotherapy, and the other due to haemotypsia not related to study treatment), and no deaths occurred in group A. After 90 days, one additional treatment-unrelated death occurred in group A and two deaths events occurred in group B (one radiation pneumonitis and one pneumonia unrelated to treatment). INTERPRETATION: A thoracic radiotherapy boost, based on interim [18F]FDG-PET, led to a meaningful local control rate with no difference in adverse events between the two groups in organs at risk, in contrast with previous attempts at thoracic radiation intensification, warranting a randomised phase 3 evaluation of such [18F]FDG-PET-guided radiotherapy dose adaptation in patients with stage III NSCLC. FUNDING: Programme Hospitalier de Recherche Clinique National 2014.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol. 2024. PMID: 39134086. doi:10.1016/S1470-2045(24)00320-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。